Peptide · Fact sheet
Thymosin alpha-1
Also known as Tα1 · thymalfasin · Zadaxin
Thymosin alpha-1 is a 28-amino-acid immune-signaling peptide studied in infections, sepsis, liver disease, and cancer-support settings. It is not FDA approved to prevent or treat infection, 'boost immunity,' treat cancer, or for any other U.S. use.
What is Thymosin alpha-1?
Thymosin alpha-1 is a synthetic version of a peptide derived from prothymosin alpha and studied as an immune modulator.
It is distinct from thymosin beta-4 and from the TB-500 fragment; the shared 'thymosin' name does not make their biology or evidence interchangeable.
Benefits & claims
Trials have explored chronic hepatitis, sepsis, immune dysfunction, respiratory infections, and combinations with cancer treatment.
Broad 'immune boost' marketing flattens condition-specific and sometimes conflicting trial findings into a claim the evidence cannot support.
What the evidence supports
- Some trials and meta-analyses report signals in selected sepsis or hepatitis outcomes.
- Other randomized studies found no significant benefit on key clinical endpoints, so results cannot support a universal immune claim.
Research areas
- Sepsis and critical-illness immune dysfunction
- Chronic hepatitis B and C
- Respiratory and other infections
- Immune support alongside cancer treatment
- Condition-specific immune modulation
- Adjunctive research in infections, liver disease, and cancer care
Dosage & frequency
No established human regimenThymosin alpha-1 has human disease-specific trials but no FDA-approved general immune-boosting or longevity regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- An adjunctive protocol for a particular infection or disease cannot establish a universal immune-support schedule.
Interactions & precautions
- Disease-specific adjunct trials do not establish a universal interaction profile with immunosuppressants or other immune-active treatments.
What is still unresolved
- Which population, route and schedule has a reproducible favorable benefit–risk balance?
Side effects & risks
- FDA identifies potential immune reactions, peptide impurities, active-ingredient characterization problems, and inadequate safety information for compounded products.
- Immune modulation can have condition-specific tradeoffs, especially in severe illness or alongside other treatments.
- Unapproved products introduce quality, purity, sterility, strength, and labeling uncertainty.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceMultiple human trials exist, including randomized studies in hepatitis and sepsis, but results vary by condition and design. The evidence does not support a general immune-enhancement claim or an FDA-approved U.S. use.
Studies
Multicenter randomized study in severe sepsis with important setting and design limits.
Randomized placebo-controlled trial whose primary response difference was not statistically significant.
Large randomized study finding no significant difference in the composite clinical endpoint.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
More capacity for work and daily activity
An author with self-described post-COVID ME/CFS reported returning to full-time work, gardening and walks after several months, while neurological symptoms remained.
Amount, frequency, route and duration could not be confirmed for this account.
Prior hyperbaric oxygen, acupuncture, pacing and the fluctuating illness complicate attribution. Diagnosis and recovery were not verified.
Read the original accountFatigue, throat symptoms and gas
An author described feeling sluggish and unwell, with throat and lymph-node discomfort and unusually frequent gas during the first four days.
Reported use in this account
- Product
- Product labeled thymosin alpha-1
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Four days at the time of the post
The author already had fatigue and self-reported Epstein–Barr-related illness. No follow-up established the cause or duration.
Read the original accountEndurance: reported experiences
More capacity for work and daily activity
An author with self-described post-COVID ME/CFS reported returning to full-time work, gardening and walks after several months, while neurological symptoms remained.
Amount, frequency, route and duration could not be confirmed for this account.
Prior hyperbaric oxygen, acupuncture, pacing and the fluctuating illness complicate attribution. Diagnosis and recovery were not verified.
Read the original accountPain: reported experiences
Fatigue, throat symptoms and gas
An author described feeling sluggish and unwell, with throat and lymph-node discomfort and unusually frequent gas during the first four days.
Reported use in this account
- Product
- Product labeled thymosin alpha-1
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Four days at the time of the post
The author already had fatigue and self-reported Epstein–Barr-related illness. No follow-up established the cause or duration.
Read the original accountDigestion: reported experiences
Fatigue, throat symptoms and gas
An author described feeling sluggish and unwell, with throat and lymph-node discomfort and unusually frequent gas during the first four days.
Reported use in this account
- Product
- Product labeled thymosin alpha-1
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Four days at the time of the post
The author already had fatigue and self-reported Epstein–Barr-related illness. No follow-up established the cause or duration.
Read the original accountNo clear change: reported experiences
No perceived reduction in recurrent illness
A commenter reported no improvement in frequent cold-like symptoms while using thymosin alpha-1.
Reported use in this account
- Product
- Product labeled thymosin alpha-1
- Amount
- 500 mcg, as reported
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Not specified clearly
The underlying illness, product contents and exposure were unverified. This does not establish either immune benefit or lack of biological activity.
Read the original accountApproval status
Thymosin alpha-1 has no FDA-approved product or indication. FDA has specifically stated that it is not approved to treat or prevent COVID-19 or any other condition and identifies compounded-product evidence and quality concerns.
No U.S. approval despite human research
Thymosin alpha-1 has human studies and non-U.S. product history, but FDA states it has no approved U.S. indication and identifies compounded-product concerns.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Which specific conditions and patient subgroups, if any, have a reproducible clinical benefit
- Long-term and uncommon harms
- How it compares with current standard treatments
- Whether findings from one formulation, country, or clinical setting transfer to another
Summary
Thymosin alpha-1 has more human research than many experimental peptides, but the evidence is condition-specific and mixed. It should not be described as a general immune booster or an FDA-approved U.S. therapy.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- fdaFDA annual report: unapproved thymosin alpha-1 claims
FDA statement that thymosin alpha-1 is not approved to treat or prevent COVID-19 or any other condition.
- pubmedETASS randomized sepsis trial
Multicenter randomized study in severe sepsis with important setting and design limits.
- pubmedPhase 3 chronic hepatitis B trial
Randomized placebo-controlled trial whose primary response difference was not statistically significant.
- pubmedRandomized study in HBV-related cirrhosis
Large randomized study finding no significant difference in the composite clinical endpoint.